Shirley Sze

Shirley Sze

Auto-generated profile, based on publicly available information

Shirley Sze

Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in JACC: Heart Failure
Verified
Journal Article
Closed access
SSShirley Sze
Shirley Sze
PPPierpaolo Pellicori
Pierpaolo Pellicori
SKSyed Kazmi
Syed Kazmi
ARAlan Rigby
Alan Rigby
JCJohn G.F. Cleland
John G.F. Cleland
ACAndrew Lawrence Clark
Andrew Lawrence Clark

1 April 2019 in JACC: Heart Failure
Verified
Journal Article
Closed access
SSShirley Sze
Shirley Sze
PPPierpaolo Pellicori
Pierpaolo Pellicori
JZJufen Zhang
Jufen Zhang
JWJoan Weston
Joan Weston
ACAndrew L. Clark
Andrew L. Clark

15 February 2017 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
SSS. Sze
S. Sze
JZJ. Zhang
J. Zhang
PPPierpaolo Pellicori
Pierpaolo Pellicori
DMD. Morgan
D. Morgan
AHA. Hoye
A. Hoye
ACA. L. Clark
A. L. Clark

5 January 2021 in Clinical Research in Cardiology
Verified
Journal Article
Open access
PDF file
SSS. Sze
S. Sze
PPP. Pellicori
P. Pellicori
JZJ. Zhang
J. Zhang
JWJ. Weston
J. Weston
ISI. B. Squire
I. B. Squire
ACA. L. Clark
A. L. Clark
Background: Frailty is common in patients with chronic heart failure (CHF) and is associated with poor outcomes. The natural history of frail patients with CHF is unknown. Methods: Frailty was assessed using the clinical frailty scale (CFS) in 467 consecutive patients with CHF (67% male, median age 76 years, median NT-proBNP 1156 ng/L) attending a routine follow-up visit. Those with CFS > 4 were classified as frail. We investigated the relation between frailty and treatments, hospitalisation and death in patients with CHF. Results: 206 patients (44%) were frail. Of 291 patients with HF with reduced ejection fraction (HeFREF), those who were frail (N = 117; 40%) were less likely to receive optimal treatment, with many not receiving a renin–angiotensin–aldosterone system inhibitor (frail: 25% vs. non-frail: 4%), a beta-blocker (16% vs. 8%) or a mineralocorticoid receptor antagonist (50% vs 41%). By 1 year, there were 56 deaths and 322 hospitalisations, of which 25 (45%) and 198 (61%), respectively, were due to non-cardiovascular (non-CV) causes. Most deaths (N = 46, 82%) and hospitalisations (N = 215, 67%) occurred in frail patients. Amongst frail patients, 43% of deaths and 64% of hospitalisations were for non-CV causes; 58% of cardiovascular (CV) deaths were due to advancing HF. Among non-frail patients, 50% of deaths and 57% of hospitalisations were for non-CV causes; all CV deaths were due to advancing HF. Conclusion: Frailty in patients with HeFREF is associated with sub-optimal medical treatment. Frail patients are more likely to die or be admitted to hospital, but whether frail or not, many events are non-CV. Graphical

27 October 2016 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
SSShirley Sze
Shirley Sze
IRIan Richmond
Ian Richmond
ABAdam Bickers
Adam Bickers
ASArabinda Saha
Arabinda Saha

2 November 2022 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
SSShirley Sze
Shirley Sze
PPPierpaolo Pellicori
Pierpaolo Pellicori
JZJufen Zhang
Jufen Zhang
JWJoan Weston
Joan Weston
ACAndrew L Clark
Andrew L Clark
Background: Frailty is common in patients with heart failure (HF) and is associated with adverse outcome, but it is uncertain how frailty should best be measured. Objectives: To compare the prognostic value of commonly-used frailty tools in ambulatory patients with HF. Methods and results: We assessed, simultaneously, three screening tools [clinical frailty scale (CFS); Derby frailty index (DFI); acute frailty network (AFN) frailty criteria), three assessment tools (Fried criteria; Edmonton frailty score (EFS); deficit index (DI)) and three physical tests (handgrip strength, timed get-up-and-go test (TUGT), 5-metre walk test (5MWT)] in consecutive patients with HF attending a routine follow-up visit. 467 patients (67% male, median age = 76 years, median NT-proBNP = 1156 ng/L) were enrolled. During a median follow-up of 554 days, 82 (18%) patients died and 201 (43%) patients were either hospitalised or died. In models corrected for age, Charlson score, haemoglobin, renal function, sodium, NYHA, atrial fibrillation (AF), and body mass index, only log[NT-proBNP] and frailty were independently associated with all-cause death. A base model for predicting mortality at 1 year including NYHA, log[NT-proBNP], sodium and AF, had a C-statistic = 0.75. Amongst screening tools: CFS (C-statistic = 0.84); amongst assessment tools: DI (C-statistic = 0.83) and amongst physical test: 5MWT (C-statistic = 0.80), increased model performance most compared with base model (P <0.05 for all). Conclusion: Frailty is strongly associated with adverse outcomes in ambulatory patients with HF. When added to a base model for predicting mortality at 1 year including NYHA, NT-proBNP, sodium, and AF, CFS provides comparable prognostic information with assessment tools taking longer to perform.